Clinical TrialsSearch results
Number of results: 1270
Other
- An open-label, multicenter, randomized, controlled, parallel-group comparative study on the effectiveness of carbohydrate-counting and calorie-counting as a dietary management in type 2 diabetic patients treated without insulin therapy
- Type 2 diabetes mellitus
- 4C-study Research Group
- 2008-12-25
Other
- A Phase 2/3 Study of SYR-322 as an Add-on to an Alpha-Glucosidase Inhibitor
- Type 2 diabetes mellitus
- Takeda Pharmaceutical Company Limited
- 2008-10-01
Other
- A Phase 2/3 Study of SYR-322 as an Add-on to a Thiazolidine
- Type 2 diabetes mellitus
- Takeda Pharmaceutical Company Limited
- 2008-10-01
Other
- A Phase 2/3 Study of SYR-322 as an Add-on to a Sulfonylurea
- Type 2 diabetes mellitus
- Takeda Pharmaceutical Company Limited
- 2009-04-01
Other
- A Phase 2/3 Study of SYR-322 as an Add-on to a Metformin
- Type 2 diabetes mellitus
- Takeda Pharmaceutical Company Limited
- 2009-04-01
Completed
- Effects of canagliflozin on renal oxygenation evaluated by BOLD MRI in patients with type 2 diabetes
- Type 2 diabetes
- Mori Katsuhito
- 2020-08-26
Completed
- A research study to see how well the new weekly medicine IcoSema, which is a combination of insulin icodec and semaglutide, controls blood sugar level in people with type 2 diabetes compared to weekly semaglutide (COMBINE 2)
- type 2 diabetes
- Miwa Hirotaka
- 2022-06-10
Completed
- A 52-week study comparing the efficacy and safety of once weekly IcoSema and daily insulin glargine 100 units/mL combined with insulin aspart, both treatment arms with or without oral anti-diabetic drugs, in participants with type 2 diabetes inadequately controlled with daily basal insulin. (NN1535-4593:COMBINE 3)
- type 2 diabetes
- Miwa Hirotaka
- 2021-11-27
Recruiting
- Prospective study of the efficacy of imeglimin and metformin against insulin secretion and resistance in patients with type 2 diabetes
- Type 2 diabetes
- Hamamoto Yoshiyuki
- 2022-08-16
Recruiting
- Osaka Metropolitan Diabetes & Obesity Trial 1
- Type 2 diabetes
- Emoto Masanori
- 2024-05-07